

Special Issue

Drug Delivery for Treatment of Neurodegenerative Diseases

Message from the Guest Editors

The failure of many molecules as CNS pharmacologically active compounds is due to different restrictions, such as poor water solubility, reduced intestinal absorption, in vivo stability, bioavailability, plasma fluctuation levels, and difficulties crossing the blood–brain barrier (BBB). Nanotechnology-based approaches, employing liposomes, micelles, dendrimers, and solid lipid nanoparticles (SLN) as drug delivery systems, are used to overcome the above-reported limitations. During the last few decades, new drug delivery technologies have emerged to treat neurodegenerative diseases; these formulations have the ability to protect drugs from chemical and enzymatic degradation, deliver the active compound to the target site with a substantial reduction of systemic toxicity, and pass physiological barriers, increasing bioavailability without resorting to high dosage forms. The aim of this Special Issue is to highlight current progress in the use of new drug delivery technologies to overcome the BBB and to target drugs to the CNS.

Guest Editors

Prof. Dr. Antonio Di Stefano

Department of Pharmacy, University G. d'Annunzio, Via dei Vestini, 66100 Chieti, Italy

Dr. Lisa Marinelli

Department of Pharmacy, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy

Deadline for manuscript submissions

closed (30 April 2020)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



mdpi.com/si/31012

Pharmaceutics
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 7.9
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).